WO2023161715 - NEXT GENERATION MRNA VACCINES
National phase entry:
Publication Number
WO/2023/161715
Publication Date
31.08.2023
International Application No.
PCT/IB2023/000094
International Filing Date
21.02.2023
Title **
[English]
NEXT GENERATION MRNA VACCINES
[French]
VACCINS D'ARNM DE NOUVELLE GÉNÉRATION
Applicants **
FUTR BIO LTDA.
Inventors
MANSUR, Daniel, Santos
BÁFICA, Andre
Priority Data
63/312,745
22.02.2022
US
63/479,974
13.01.2023
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3607 | |
| EPO | Filing, Examination, Granting | 23826 | |
| Japan | Filing, Examination, Granting | 2918 | |
| South Korea | Filing, Examination, Granting | 3537 | |
| USA | Filing, Examination, Granting | 10190 |
Total:
44,078
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
Described herein are next generation vaccine compositions, including mRNA vaccines having flavivirus untranslated regions and vaccines comprising a (major histocompatibility complex) MHC binding peptide.[French]
L'invention concerne des compositions de vaccin de nouvelle génération, comprenant des vaccins d'ARNm ayant des régions non traduites de flavivirus et des vaccins comprenant un peptide de liaison MHC (complexe majeur d'histocompatibilité).